Maven Securities’s Harmony Biosciences HRMY Stock Holding History

Maven Securities’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,277	Closed	-$206K	–	681
2020 Q3	$206K	Buy	+6,277	New	+$229K	0.02%	554

Other funds holding HRMY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's HRMY Position: Q4 2020 in Review

Maven Securities sold out of Harmony Biosciences (HRMY) in Q4 2020, closing a stake of 6,277 shares — an estimated $206K sold.

Maven Securities first reported a position in HRMY in Q3 2020 and held it in 1 quarter. The position peaked at $206K in Q3 2020. 59 funds tracked by Wall St. Rank hold HRMY as of Q4 2020.

Maven Securities reported no remaining Harmony Biosciences position as of Q4 2020 after selling out during the quarter.
Maven Securities sold 6,277 Harmony Biosciences shares in Q4 2020, an estimated $206K.
Maven Securities first reported a position in Harmony Biosciences in Q3 2020 and held it in 1 quarter.
Maven Securities's Harmony Biosciences position peaked at $206K in Q3 2020.
59 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.